GlaxoSmithKline Annual Review 2002 - Corporate Executive Team

The Impact of Medicines - Annual Review 2002

The executive management of the Group is through the
Corporate Executive Team (CET), comprising the Chief
Executive Officer, the Chief Financial Officer and other
senior managers.

The executive management of the Group is through the
Corporate Executive Team (CET), comprising the Chief
Executive Officer, the Chief Financial Officer and other
senior managers.

Corporate Executive Team

JP Garnier

JP GARNIER, Chief Executive Officer: As Chief Executive Officer, JP is the link between the Board and staff, and oversees all operational aspects including establishing policies, objectives and initiatives, and directing long term strategy. He was formerly Chief Executive Officer of SmithKline Beecham, having joined the Group in 1990.

Rupert Bondy

RUPERT BONDY, Senior Vice President and General Counsel: Rupert is responsible for legal matters across the Group, together with environmental, health and safety issues, insurance and security. He was a lawyer in private practice before joining SmithKline Beecham in 1995 as Senior Counsel.

Ford Calhoun

FORD CALHOUN,Chief Information Officer: Ford is responsible for information technology, a global function that enables key business processes across all parts of the Group. With doctoral and post-doctoral training in microbiology, genetics, biomathematics and computer science, Ford joined Smith Kline and French in 1984.

John Coombe

JOHN COOMBE, Chief Financial Officer: As head of the finance function, John is responsible for activities such as financial reporting and control, tax and treasury, investor relations, finance systems, internal audit and real estate. He joined Glaxo in 1986 as Group Financial Controller and was appointed Group Finance Director in 1992.

Dan Phelan

DAN PHELAN, Senior Vice President: Human Resources Dan is responsible for benefits, compensation, recruitment, organisation development, leadership development and succession planning, human resource information systems and employee health management. He joined Smith Kline and French in 1981 and in 1994 was appointed Senior Vice President and Director, Human Resources, SmithKline Beecham.

Howard Pien

HOWARD PIEN, President Pharmaceuticals International: Howard leads the pharmaceutical operations outside the USA and most of Europe, covering more than 100 countries that account for over 82 per cent of the world's population. He joined SmithKline Beecham in 1991 and in 1998 was appointed President, Pharmaceuticals.

David Pulman

DAVID PULMAN, President Global Manufacturing and Supply: Appointed to the post in December 2002, David is responsible for the global manufacturing and supply chain network. He joined Glaxo in 1978 and prior to his most recent posting was responsible for the North American supply network, manufacturing strategy and logistics.

David Stout

DAVID STOUT,President Pharmaceutical Operations: David was President of US Pharmaceuticals until he was appointed to his current position in January 2003. He is responsible for the global pharmaceuticals business as well as the global vaccines business. He joined SmithKline Beecham in 1996 as head of its US Sales and Marketing function, and in 1998 became President, Pharmaceuticals, North America.

Chris Viehbacher

CHRIS VIEHBACHER, President US Pharmaceuticals: Responsible for European pharmaceuticals operations until the end of 2002, Chris took over the US pharmaceuticals operations in January 2003. He joined Wellcome in 1988 and became Director, Continental Europe, at Glaxo Wellcome in 1999.

Andrew Witty

ANDREW WITTY, President Pharmaceuticals Europe: Andrew is responsible for the Group's pharmaceuticals operations in Europe, a post he took up in January 2003 when he was appointed to the CET. Andrew joined Glaxo in 1985 and at GlaxoSmithKline was Senior Vice President, Asia Pacific, until his current post.

Tachi Yamada

TACHI YAMADA, Chairman Research & development: Tachi leads the Group's complex business of drug discovery and development - creating new medicines through research. He joined SmithKline Beecham in 1994 as a Non-Executive member of the Board and became Chairman, R&D, Pharmaceuticals in 1999.

Jennie Younger

JENNIE YOUNGER, Senior Vice President: Corporate Communications and Community Partnerships Jennie is responsible for the Group's internal and external communications, its image and partnerships with communities of the world. She joined Glaxo Wellcome in 1996 as Director of Investor Relations.

Jack Ziegler

JACK ZIEGLER, President Consumer Healthcare: Jack is head of the global Consumer Healthcare business, which produces oral healthcare, over-the-counter medicines and nutritional healthcareproducts. He joined SmithKline Beecham in 1991 and in 1998 was appointed President of the Consumer Healthcare business.

Other members: James Palmer and Tim Tyson left the Group on 1st December 2002 to pursue other roles in the pharmaceutical industry. Bob Ingram retired on 31st December 2002 but will continue to work part-time as Vice Chairman of Pharmaceuticals, acting as a special advisor to the Group and will attend CET meetings in that capacity.

	Annual Review 2002 Home \| Reporting Front Page \| Downloads \| Main Site
	Updated March 28, 2003 - © 2005 GlaxoSmithKline - All Rights Reserved Legal Notices - Privacy Statement